UNASSIGNED: Random-effects meta-analysis was conducted to pool effect estimates for comparison between CAR-T cell therapy and SOC. Mixed treatment comparisons were made using a frequentist network meta-analysis approach.
UNASSIGNED: Meta-analysis of three trials with 865 patients showed significant improvement in event-free survival (EFS: HR: 0.51; 95% CI: 0.27-0.97; I2: 92%), progression-free survival (PFS: HR: 0.47; 95% CI: 0.37-0.60; I2: 0%) with CAR-T cell therapy compared to SOC. Although there was a signal of potential overall survival (OS) improvement with CAR-T cell therapy, the difference was not statistically significant between the two groups (HR 0.76; 95% CI: 0.56 to 1.03; I2: 29%). Mixed treatment comparisons showed significant EFS benefit with liso-cel (HR: 0.37; 95% CI: 0.22-0.61) and axi-cel (HR: 0.42; 95% CI: 0.29-0.61) compared to tisa-cel.
UNASSIGNED: CAR-T cell therapy, as a second-line treatment, appears to be effective in achieving higher response rates and delaying the disease progression compared to SOC in R/R DLBCL.
■进行随机效应荟萃分析以汇集效应估计值,以比较CAR-T细胞疗法和SOC。使用频率网络荟萃分析方法进行混合治疗比较。
■对三个865例患者进行的荟萃分析显示,无事件生存率显着改善(EFS:HR:0.51;95%CI:0.27-0.97;I2:92%),与SOC相比,CAR-T细胞疗法的无进展生存期(PFS:HR:0.47;95%CI:0.37-0.60;I2:0%)。尽管CAR-T细胞疗法有潜在的总生存期(OS)改善的信号,两组之间的差异无统计学意义(HR0.76;95%CI:0.56至1.03;I2:29%)。混合治疗比较显示,与tisa-cel相比,采用Liso-cel(HR:0.37;95%CI:0.22-0.61)和axi-cel(HR:0.42;95%CI:0.29-0.61)的EFS益处显着。
■CAR-T细胞疗法,作为二线治疗,与R/RDLBCL的SOC相比,似乎可有效实现更高的应答率和延迟疾病进展。